Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31147883 | 1.00 | TAAR1 (0.59) | TAAR1ESR2CYP11B2NFE2L2HSD17B1 | |
| SCHEMBL30068301 | 1.00 | TAAR1 (0.59) | TAAR1ESR2CYP11B2NFE2L2HSD17B1 | |
| SCHEMBL198702 | 0.84 | TAAR1 (0.68) | TAAR1ESR2CYP11B2NFE2L2HSD17B1 | |
| SCHEMBL257773 | 0.82 | TNKS2 (0.56) | TAAR1ESR2CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL12384873 | 0.82 | TAAR1 (0.55) | TAAR1ESR2CYP11B2HSD17B1HSD17B2 | |
| SCHEMBL16605628 | 0.82 | TAAR1 (0.65) | TAAR1ESR2CYP11B2NFE2L2HSD17B1 | |
| SCHEMBL16605626 | 0.82 | TAAR1 (0.65) | TAAR1ESR2CYP11B2NFE2L2HSD17B1 | |
| SCHEMBL29628985 | 0.82 | TAAR1 (0.65) | TAAR1ESR2CYP11B2NFE2L2HSD17B1 | |
| SCHEMBL13741967 | 0.82 | CYP17A1 (0.52) | ESR2CYP11B2HSD17B1HSD17B2CYP17A1 | |
| SCHEMBL19665049 | 0.81 | TAAR1 (0.54) | TAAR1ESR2CYP11B2HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902519-A | Liquid crystal composition comprising five-membered heterocyclic ring, reverse mode polymer dispersed liquid crystal element and related selectively dimmable device | 日东电工株式会社 | 2020-11-06 | — | — | CN | disclosed |
| WO-2019147842-A1 | LIQUID CRYSTAL COMPOSITION CONTAINING A FIVE-MEMBERED HETEROCYCLIC RING, REVERSE-MODE POLYMER DISPERSED LIQUID CRYSTAL ELEMENT, AND ASSOCIATED SELECTIVELY DIMMABLE DEVICE | NITTO DENKO CORPORATION (JP) | 2019-08-01 | — | — | WO | disclosed |
| US-10155739-B2 | Halogenated S-(perfluoroalkyl)dibenzothiophenium salt and its production methods | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2018-12-18 | — | — | US | disclosed |
| US-20170349567-A1 | Halogenated S-(perfluoroalkyl)dibenzothiophenium salt and its production methods | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155739-B2 | Halogenated S-(perfluoroalkyl)dibenzothiophenium salt and its production methods | FGFR2, SULT1A1, PFAS | TAAR1 3061/4885ESR2 2026/4885CYP11B2 733/4885 |
| US-20170349567-A1 | Halogenated S-(perfluoroalkyl)dibenzothiophenium salt and its production methods | FGFR2, SULT1A1, PFAS | TAAR1 3061/4885ESR2 2026/4885CYP11B2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.